{"classes":[{"categories":[{"measurements":[{"comment":"NA = value cannot be estimated due to censored data","groupId":"OG000","lowerLimit":"6.0","upperLimit":"NA","value":"7.4"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"10.3","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"DOR was defined in responders as the time from central documentation of tumor response date of first response in the confirmation sequence) to the earlier of disease progression as determined by the central radiological reviewer, or death without centrally documented progression. A responder was a patient who had a confirmed best tumor response on-study of CR or PR, as determined by the central radiological reviewer per mRECIST criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"The secondary efficacy analysis (DOR) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause.","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}